Antibody Conjugates

Home - antibody

Antibody Conjugates

Antibody Conjugates

CONTACT US

Randox is the primary manufacturer of high-quality recombinant immunoglobulins including IgG, IgA and IgM isotypes which are expressed using a proprietary CHO cell technology

See below our new selection of ready-conjugated off the shelf antibody HRP-conjugates

BioReagents Icon

 

 

Our Range of BioReagents

BioReagents Icon

Recombinant Antibodies

Recombinant Antibodies

CONTACT US

Randox is the primary manufacturer of high-quality recombinant immunoglobulins including IgG, IgA and IgM isotypes which are expressed using a proprietary CHO cell technology

We offer a range of recombinant human, sheep and mouse antibodies which are validated in a range of traditional immunoassay formats, western blots and as control reagents in infectious disease and autoantibody serological assays.

BioReagents Icon

 

 

Click here to discover our new selection of ready-conjugates off the shelf antibody HRP-conjugates

Antibody Conjugates

Our Range of BioReagents

BioReagents Icon

SdAbs

SdAbs

CONTACT US

Our scientists highly recommend the use of Single Domain Antibody Fragments (sdAbs) as they are more stable, adaptable and easily humanised, making them ideal for therapeutic products.

 

Randox have a specialised offering of sdAbs for research and therapeutic applications.

BioReagents Icon
 SdAbs provide a new mechanism for the generation of antibody therapeutics and offer numerous advantages such as better tissue penetration, ease of expression, stability and uniformity of product.
They also have benefits in traditional settings, due to their small size a much higher coating concentration can be achieved for assay development.

 

 

Research & Therapeutic Applications

 

Our Range of BioReagents

BioReagents Icon

Conjugates

Conjugates

CONTACT US
Randox’s antigen-HRP conjugates are optimized for use with Randox polyclonal antibodies for the development of immunoassays. All HRP-conjugates are provided in a conjugate stabilising solution, specifically formulated in-house to prolong the shelf-life of newly conjugated material, enhancing the conjugate’s overall performance and reliability within your immunoassay.
BioReagents Icon

Our Range of BioReagents

BioReagents Icon

Recombinant Proteins

Recombinant Proteins

CONTACT US

 In-house experts at Randox are able to provide the recombinant proteins in the desired buffers, thus offering their knowledge in supporting the customers’ research.

Every time a gene is introduced into a plasmid and transformed in various biological systems such as bacteria and mammalian cells; it expresses to produce recombinant proteins. The production of such proteins in prokaryotes provides multiple advantages, such as low cost, rapid cell growth, high yield, and a relatively short expression period.
On the other hand, whenever a protein is required with post-translational modifications and precise folding, mammalian cells are chosen as the expression hosts. With a wide range of tags used, it is ensured that the expressed proteins are purified to a high standard.
BioReagents Icon

 

 

Our Range of BioReagents

BioReagents Icon

Monoclonal

Monoclonal Antibodies

Randox Biosciences offer an extensive range of monoclonal antibodies against biochemical markers, drugs of abuse and drug residues for use in both research and pharmaceutical development.
Using sheep as the host species, Randox are able to offer an alternative to current monoclonal antibodies available on the market.

 Producing a wide range of monoclonal antibodies, our products offer several advantages including specificity in producing high quality antibodies for a required target with high affinity.

BioReagents Icon

Our Range of BioReagents

BioReagents Icon

CDx & BioPharma Services

CDx & BIOPHARMA SERVICES

Offering a collaborative CDx partnership approach.

 

As an established IVD company, Randox Biosciences offers tailored development and testing solutions to support faster, more effective and safer development of new drugs.

We have a wide range of in-house capabilities, ranging from the selection and patenting of novel biomarkers; manufacture of bioreagents; production of single and multiplex RUO and IVD grade tests; quality control; provision of clinical laboratory services; regulatory expertise and worldwide distribution.

Pharma Icon

Why Partner with Randox?

Pharmaceutical and biotech companies are increasingly investing in the research and development of new therapies to address the world’s growing need for earlier and more effective patient treatment.

Randox Biosciences is dedicated to the improvement of personalised diagnostic, prognostic, and predictive assays. We aim to help Pharma Biotechs and CROs move away from a “one treatment fits all” approach and help get a better understanding of the complexity and variability of diseases and increase efficacy of treatment. A key element to realizing the potential for personalized medicine is companion diagnostic (CDx) development. Randox have key expertise in all elements of CDx and diagnostic development and offer a fully flexible partnership to accommodate your needs, providing you with tailored protein & molecular assays.

Biosciences Accreditations

Randox Biosciences can be your CDx and biomarker assay development partner from early phase trials through to drug launch, addressing all assay requirements in the process, including development of raw materials and assays, verification and validation studies, clinical trial sample analysis, regulatory submissions and co-commercialisation.

Complete CDx Partner Approach

CDx Development timeline

CDx Assay Formats

Randox Biosciences is focused on advancing precision medicine through high quality, flexible assay development. We can offer the full package of Diagnostic and CDx assay development with a range of technologies and platforms for use in clinical trials. 

 

We invite researchers to design their specific multiplex custom array, containing selected biomarkers, ensuring maximum output from a limited sample supply. Our proprietary multiplex biochip array technology can be used in early exploratory biomarker stages and can be brought through to IVD/CDx grade.

ENQUIRE NOW
Biochip Render Lit Blue - Lighter

CDx Drug and Diagnostic Development Process 

Pharma Icon
null

Development of Raw Materials

- Extensive portfolio of over 900 products for R&D applications

- Products manufactured under ISO13485 accreditation including mAbs, PAS, HRPs, sdAbs, scFvs

- Capable of custom antibody and protein development

null

Assay Development

- Randox offer a range of technologies and platforms for use in clinical trials

- Our Biochip technology can be used in early exploratory biomarker stages and brought through to IVD/ CDx grade.

- Comprehensive OEM capabilities for developing assays on any platform.

- Assays developed under full design control and ISO13485 accreditation

null

Sample Testing

- ISO17025, ISO15189 and GCP accredited laboratories located throughout the UK, Ireland and USA.

- Randox Clinical Laboratory Services (RCLS) can be used to meet bespoke sample analysis needs.

- Strong global network with 3rd party laboratories to ensure clinical trial requirements are met across the world.

null

Verification & Validation

- Performance of in depth multi lot verifications following CLSI guidelines to ensure full performance requirements are met

- Provide support for regulatory submissions and approvals

- Validation of assay performance and reproducibility across multiple sites

null

Regulatory Submission

- Experienced in-house regulatory teams provide FULL regulatory support preparing IVD/ CDx submissions and applications for approval.

- Regulatory and Development teams work closely in collaboration with the pharma partner to ensure a timely submission while keeping in line with country specific requirements

- 954 licences across the globe and over 3800 licensed products

null

Commercialization

- Pre and Post launch support with laboratory, clinician, patient and KOL engagement.

- Strong global laboratory and distribution networks, in house sales and marketing teams, with operations in over 145 countries.

- Capable of manufacturing customised sample collection kits under full design control

Randox Platforms

 


Why are Neutralising Antibody tests important now?

COVID-19 Testing        News        Contact Us

27 October 2021- Why are Neutralising Antibody tests important now? 

Being prone to more frequent infections may mean that you have a weak immune system. With everything going on in the world, including COVID-19, this is important information that you need to know about yourself. As it stands, the pace of the vaccine booster rollout has slowed down and priority is given to people who are most vulnerable from developing a COVID-19 infection. This will offer those individuals the fullest protection against the virus this winter.  According to John Roberts, from the COVID-19 Actuaries Response Group, “At the start of the booster campaign, the health secretary Sajid Javid said: ‘We will protect the most vulnerable through the winter months’. But at the current rate it is going to be well through winter before we get through those first groups.”  This was stated on a BBC news article. (1)

This leads into the question that everybody is wondering…. Do we really need the booster vaccine? Infectious diseases expert, Professor Angus Dalgleish has commented during an interview on Good morning Britain that we should try another strategy.  A strategy where we should test people’s immunity first to see if they need the booster vaccine. He stated, “It should not be difficult for one test to see what your immune response to your last vaccine is or if you have had very bad COVID, have you got a good immune response and do you need the booster”. (2)

Laith Jamal Abu-Raddad, an infectious-disease epidemiologist at Weill Cornell Medicine—Qatar in Doha has also stated in an article from Nature that “Wasting resources on boosters for those who are already protected against severe disease does not really make too much sense,” (3)

The Randox SARS-CoV-2 Neutralising Antibody tests detects antibody levels post-vaccination to determine eligibility for a booster vaccination. These tests utilise patented biochip technology to detect neutralising antibodies to the Wuhan and Delta SARS-CoV-2 variants. There is a need for tests of this kind to provide an accurate estimate of immunity, monitor vaccine effectiveness and the frequency of post-vaccine breakthrough infections with variants of concern. Recent studies indicate that the delta variant is capable of re-infection even in fully vaccinated individuals and that a significant proportion of fully vaccinated individuals with breakthrough infections can transmit the virus to others.

The SARS-CoV-2 Neutralising Antibody tests are a quick and effective way to determine:

  • Longevity of immune response with response to post-vaccine infection, and variants of concern.
  • Population surveillance and testing of those at risk of sub-optimal vaccine response.
  • Measure antibody levels post-vaccination to determine eligibility for a booster vaccination.
  • Accurately detects antibodies that are capable of inhibiting virus replication and neutralizing the infectivity of the virus.

 

Want to know more?

For more information on SARS-CoV-2 Neutralising Antibody tests please visit the link below,

SARS-CoV-2 Neutralising Antibody Test | Randox Laboratories

Visit booking.randox.ie to book your COVID-19 antibody test today!

Alternatively contact us via email: marketing@randox.com

Sources linked-

  1. Covid: Is the pace of the vaccine booster rollout too slow? – BBC News
  2. ‘Don’t Panic’ Professors Questioned On The Rise In Covid Cases In England Sparking Concern | GMB – YouTube
  3. https://www.nature.com/articles/d41586-021-02158-6

Related COVID-19 Products and Services

CERTIFLY LATERAL FLOW

HOME TEST - PCR

ANTIBODY TEST

LABORATORY TOOLS


SARS-CoV-2 Neutralising Antibody Test

SARS-CoV-2 Neutralising Antibody Tests

Measuring neutralising antibodies to Wild Type (Wuhan) & Delta variants following vaccination or natural infection

Accurate indicator of protective immunity against SARS-CoV-2 variants

  • null
    Determine if an effective antibody response has been generated to circulating SARS-CoV-2 variants following vaccination or natural infection
  • null
    Identify individuals with a sub-optimal vaccine response to inform eligibility for booster vaccination
  • null
    Provide accurate estimates of herd immunity at a local and national population level

The Randox CE marked SARS-CoV-2 Wild Type Surrogate Virus Neutralisation Assay (EV4454) and Delta SARS-CoV-2 Surrogate Virus Neutralisation Assay (EV4477) detect antibodies that block interaction of the spike protein receptor-binding domain (RBD) and angiotensin-converting enzyme 2 (ACE2).

Rapid, high throughput tests that measure neutralising antibodies against circulating SARS-CoV-2 variants are of significant interest to Clinical, Pharmaceutical, Government and Research organisations. Vaccine breakdown is of growing concern globally with the emergence of SARS-CoV-2 variants such as the now dominant Delta strain. Randox have available innovative testing solutions to accurately measure protection against infection and to identify individuals where booster vaccination is required. This can help reduce infection rates and onward virus transmission by ensuring sufficient levels of herd immunity.

 

 

Ordering Information

AssayCat Code
Wild Type SARS-CoV-2 Surrogate Virus Neutralisation AssayEV4454
Delta SARS-CoV-2 Surrogate Virus Neutralisation AssayEV4477
Evidence Investigator AnalyserEV3602

Available Platform

Evidence Investigator

Specificty of 100% and sensitivity of 98% compared ro coventional virus neutralisation tests

Semi-automated solution suitable for medium to high throughput testing

Direct sample addition to biochip well.  No off-board sample incubation required

Results available in 1.5 hours without the need for biosafety level 3 cabinet

Limited sample volume requirements

Comprehensive immunoassay and molecular test menu available

Evidence Investigator

Randox Clinical Laboratory Service (RCLS)

RCLS specialise in offering an esoteric biomarker testing service, utilising the experience and knowledge Randox has built over 40 years of producing high quality in vitro diagnostics.

RCLS strive to provide a clinical laboratory testing service to meet the time sensitive, bespoke requirements of research and clinical trial projects globally.

Accredited laboratory service

Cost effective solution

Offers greater flexibility

Want to know more?

Contact us or visit our COVID-19 Monitoring & Management page

Related Products

EVidence Investigator

SARS-CoV-2 RBD & NP Array

COVID-19

COVID-19 Disease Management